Beat Childhood Cancer Specimen Banking and Data Registry
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorGiselle Sholler
About this trial
This is an observational data registry study of pediatric cancer patients at participating Beat Childhood Cancer Consortium sites involving specimen banking and data collection.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
No age restrictions
Subjects with suspected or confirmed cancers of childhood, adolescence, or young adulthood.
Survivors of a cancer of childhood, adolescence, or young adulthood (> 6 months off last therapy for cancer)
Subjects with a disease-matched condition
Disqualifiers
Subject or his/her legally authorized representative (where applicable) did not consent for specimen banking and data collection for this study.
Trial population
Pediatric cancer subjects, survivorship, and healthy volunteers at The Pennsylvania State University and participating Beat Childhood Cancer Research Consortium sites.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
No intervention- registry only
Other interventionNo intervention- registry only
Treatment groups
1,000 Participants
are divided into 1 treatment groupGroup A: Patients with suspected or confirmed pediatric solid tumors1 intervention
Trial outcomes
Primary outcomes
1
Create a data registry of clinical and molecular/genomic data
Create a data registry of clinical and molecular/genomic data from cancer patients who have undergone biopsy or surgical resection for clinical care to better understand the relationship between genomic and molecular information and clinical outcomes.
Time frame
10 Years2
Determine number and types of genomic alterations within tumor types/subtypes
Define genomic landscape of pediatric cancers through the determination of the number and types of genomic alterations within tumor types/subtypes, across tumor types, and tumor evolution over time.
Time frame
10 Years3
Evaluate the rate of actionable genomic alternations
Evaluate the rate of actionable genomic alternations resulting in associated targeted therapies relative to all actionable genomic alterations.
Time frame
10 Years4
Evaluate the correlation of baseline genomic alterations with clinical outcome.
Evaluate the correlation of baseline genomic alterations with clinical outcome.
Time frame
10 YearsSecondary outcomes
1
Bank additional specimens available for future research projects
Bank additional specimens available for future research projects
Time frame
10 Years2
Develop cell line and xenograft models of pediatric cancers for future research
Develop cell line and xenograft models of pediatric cancers for future research
Time frame
10 Years3
Identify biomarkers that predict risks of disease states in subject controls that did not receive cancer therapy.
Identify biomarkers that predict risks of disease states in subject controls that did not receive cancer therapy.
Time frame
10 Years4
Identify biomarkers that may predict risk of disease dependent on sex, race, ethnicity, or the presence of comorbidities.
Identify biomarkers that may predict risk of disease dependent on sex, race, ethnicity, or the presence of comorbidities.
Time frame
10 YearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Giselle Sholler
Lead sponsor
Milton S. Hershey Medical Center
Sponsor institution
Source ClinicalTrials.gov